Nishio, T., Koyama, Y., Liu, X., Rosenthal, S. B., Yamamoto, G., Fuji, H., . . . Kisseleva, T. (2021). Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A.
Citação norma ChicagoNishio, Takahiro, et al. "Immunotherapy-based Targeting of MSLN(+) Activated Portal Fibroblasts Is a Strategy for Treatment of Cholestatic Liver Fibrosis." Proc Natl Acad Sci U S A 2021.
Citação norma MLANishio, Takahiro, et al. "Immunotherapy-based Targeting of MSLN(+) Activated Portal Fibroblasts Is a Strategy for Treatment of Cholestatic Liver Fibrosis." Proc Natl Acad Sci U S A 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.